MCID: CRC014
MIFTS: 40

Carcinoid Tumors, Intestinal malady

Categories: Genetic diseases, Endocrine diseases, Rare diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Carcinoid Tumors, Intestinal

About this section

Aliases & Descriptions for Carcinoid Tumors, Intestinal:

Name: Carcinoid Tumors, Intestinal 51 12
Gastrointestinal Carcinoid Tumor 69 49 67
Carcinoid Tumor 38 67
Argentaffinoma 69 67
Carcinoid 69 49
Carcinoid Tumor and Carcinoid Syndrome 53
 
Carcinoid Tumor No Icd-O Subtype 67
Carcinoid Tumor of Intestine 67
Copper Toxicosis, Idiopathic 67
Intestinal Carcinoid Tumor 69
Go-Coa-Tat 38
Ict 69

Characteristics:

HPO:

63
carcinoid tumors, intestinal:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM51 114900
Orphanet53 ORPHA100093
ICD10 via Orphanet30 E34.0
MedGen36 C0349535
MeSH38 D002276

Summaries for Carcinoid Tumors, Intestinal

About this section
UniProtKB/Swiss-Prot:69 Intestinal carcinoid tumor: A yellow, well-differentiated, circumscribed tumor that arises from enterochromaffin cells in the small intestine or, less frequently, in other parts of the gastrointestinal tract.

MalaCards based summary: Carcinoid Tumors, Intestinal, also known as gastrointestinal carcinoid tumor, is related to appendix carcinoid tumor and spinal chordoma, and has symptoms including intestinal carcinoid An important gene associated with Carcinoid Tumors, Intestinal is SDHD (Succinate Dehydrogenase Complex Subunit D). Affiliated tissues include liver, breast and lung, and related mouse phenotypes are neoplasm and digestive/alimentary.

Description from OMIM:51 114900

Related Diseases for Carcinoid Tumors, Intestinal

About this section

Diseases related to Carcinoid Tumors, Intestinal via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 148)
idRelated DiseaseScoreTop Affiliating Genes
1appendix carcinoid tumor12.1
2spinal chordoma10.5CHGA, SST
3extragonadal germ cell cancer10.5CHGA, SST
4ovary mixed epithelial carcinoma10.5CHGA, SYP
5gastrinoma10.5CHGA, SST
6esophagus small cell carcinoma10.5CHGA, SYP
7spinal muscular atrophy10.5CHGA, SST
8lice infestation10.5CHGA, SYP
9childhood malignant schwannoma10.5CHGA, SYP
10diabetes mellitus, transient neonatal, 310.5CHGA, SST
11microglandular adenosis of breast10.4CHGA, SYP
12clear cell adenoma10.4CHGA, SYP
13osteoblastoma10.4CHGA, SYP
14esophagus adenocarcinoma10.4CHGA, SYP
15fraxf syndrome10.4CHGA, SYP
16froelich syndrome10.4CHGA, SYP
17adult teratoma10.4NKX2-1, SYP
18mixed endometrial stromal and smooth muscle tumor10.4CHGA, SYP
19lumbar plexus neoplasm10.4CHGA, SYP
20cutaneous mastocytosis10.4CHGA, SYP
21mast-cell sarcoma10.4NKX2-1, SYP
22pancreatic serous cystic neoplasm10.4CHGA, SYP
23pilocytic astrocytoma10.4CHGA, SYP
24bone remodeling disease10.4NKX2-1, SYP
25gastrointestinal anthrax10.4CHGA, SST
26subpulmonary stenosis10.4CHGA, SYP
27angora hair nevus10.4NKX2-1, SYP
28diencephalic astrocytomas10.4CHGA, SYP
29brain stem ependymoma10.4CHGA, SYP
30pneumonia10.4CHGA, SYP
31ovarian clear cell malignant adenofibroma10.4CHGA, SYP
32kartagener syndrome10.4CHGA, SST
33retinal melanoma10.4SST, SYP
34rectum signet ring adenocarcinoma10.4CHGA, SYP
35pancreatic agenesis10.4CHGA, SYP
36ovarian cyst10.4CHGA, POMC
37parathyroid transitional clear cell adenoma10.4CHGA, MEN1
38cranial nerve iii tumor10.4CHGA, SYP
39norwegian scabies10.4CHGA, POMC
40tricuspid valve stenosis10.4CHGA, SYP
41neurilemmoma of the fifth cranial nerve10.4SDHD, SYP
42paranasal sinus cancer, adult10.4CHGA, SYP
43large intestine lipoma10.4CHGA, SYP
44brain angioma10.3POMC, SST
45mucinous adenocarcinoma10.3CHGA, SYP
46tabes dorsalis10.3SST, SYP
47mobitz type ii atrioventricular block10.3POMC, SST
48mesenchymoma10.3NKX2-1, SYP
49kummell's disease10.3CHGA, SYP
50lipid-rich carcinoma10.3POMC, SST

Graphical network of the top 20 diseases related to Carcinoid Tumors, Intestinal:



Diseases related to carcinoid tumors, intestinal

Symptoms for Carcinoid Tumors, Intestinal

About this section

Symptoms by clinical synopsis from OMIM:

114900

Clinical features from OMIM:

114900

Human phenotypes related to Carcinoid Tumors, Intestinal:

 63
id Description HPO Frequency HPO Source Accession
1 intestinal carcinoid63 HP:0006723

Drugs & Therapeutics for Carcinoid Tumors, Intestinal

About this section

Drugs for Carcinoid Tumors, Intestinal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 192)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Oxaliplatinapproved, investigationalPhase 4, Phase 2, Phase 1141261825-94-35310940, 9887054, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
2
SomatostatinapprovedPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 122938916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
3Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13868
4Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112767
5Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112778
6HormonesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113979
7Hypoglycemic AgentsPhase 4, Phase 2, Early Phase 15733
8Insulin, Globin ZincPhase 4, Phase 24523
9insulinPhase 4, Phase 24524
10ColaNutraceuticalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11881
11
Fentanylapproved, illicit, investigational, vet_approvedPhase 3773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
12
OndansetronapprovedPhase 330999614-02-54595
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
99614-01-4 (mono-hydrochloride)
99614-02-5
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
GR 38032
GR 38032X
GR-38032F
GR38032F
HMS2090H16
I06-0687
I06-1329
 
L000456
LS-172305
LS-51878
MolPort-001-944-253
NCI60_022780
Novo-ondansetron
Ondansetron
Ondansetron (JAN/USP/INN)
Ondansetron [USAN:INN:BAN]
Ondansetron, (+,-)-Isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
SN-307
SPBio_002938
STK370548
STOCK4S-10990
Sandoz ondansetron
TL8006071
TimTec1_001750
UNII-4AF302ESOS
ZOFRAN IN PLASTIC CONTAINER
Zofran
Zofran ODT
Zofran ODT (TN)
Zofran odt
Zophren
Zudan
ondansetron
ondansetron (Zofran)
13
Dexamethasoneapproved, investigational, vet_approvedPhase 3, Phase 2208450-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
14
Octreotideapproved, investigationalPhase 3, Phase 221383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
15Anti-Infective AgentsPhase 3, Phase 2, Phase 121402
16Interferon-alphaPhase 3, Phase 21139
17Antiviral AgentsPhase 3, Phase 2, Phase 19732
18interferonsPhase 3, Phase 2, Phase 12137
19Gastrointestinal AgentsPhase 3, Phase 1, Phase 28109
20HIV Protease InhibitorsPhase 35319
21Dexamethasone acetatePhase 3, Phase 220841177-87-3
22Dexamethasone 21-phosphatePhase 3, Phase 22084
23Neurotransmitter AgentsPhase 3, Phase 217734
24glucocorticoidsPhase 34920
25
protease inhibitorsPhase 35320
Synonyms:
 
protease inhibitors
26Tranquilizing AgentsPhase 34164
27Serotonin AntagonistsPhase 3, Phase 21381
28Serotonin AgentsPhase 3, Phase 23102
29Dermatologic AgentsPhase 3, Phase 25674
30Psychotropic DrugsPhase 36279
31
SerotoninPhase 3, Phase 2356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
32Anesthetics, GeneralPhase 32787
33Anesthetics, IntravenousPhase 32406
34Central Nervous System DepressantsPhase 312806
35Analgesics, OpioidPhase 33091
36AnalgesicsPhase 3, Phase 111287
37BB 1101Phase 3, Phase 22084
38Antineoplastic Agents, HormonalPhase 35407
39Adjuvants, AnesthesiaPhase 31588
40NarcoticsPhase 33486
41AnestheticsPhase 3, Phase 29001
42Anti-Inflammatory AgentsPhase 310355
43Antipsychotic AgentsPhase 32359
44Autonomic AgentsPhase 3, Phase 29774
45AntiemeticsPhase 33888
46AntipruriticsPhase 3864
47Peripheral Nervous System AgentsPhase 3, Phase 2, Phase 122776
48Anti-Anxiety AgentsPhase 31816
49pancreatic polypeptidePhase 3, Phase 2, Phase 120
50Pharmaceutical SolutionsPhase 37793

Interventional clinical trials:

(show top 50)    (show all 140)
idNameStatusNCT IDPhase
1Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerUnknown statusNCT00274885Phase 4
2Pasireotide Treatment for Neuroendocrine TumorWithdrawnNCT02779257Phase 4
3Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or MelanomaUnknown statusNCT00002455Phase 3
4TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)CompletedNCT01677910Phase 3
5Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid DiseaseCompletedNCT00690430Phase 3
6Telotristat Etiprate for Carcinoid Syndrome TherapyCompletedNCT02063659Phase 3
7Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
8Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper AbdomenCompletedNCT00016380Phase 3
9An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing RadiationCompletedNCT00132704Phase 3
10177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETsRecruitingNCT01842165Phase 3
11A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursActive, not recruitingNCT01578239Phase 3
12[68 Ga]-DOTANOC PET/CT in GEP-NETsNot yet recruitingNCT02608203Phase 2, Phase 3
13Randomized Phase III of PRRT Versus InterferonWithdrawnNCT01860742Phase 3
14Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract CancerUnknown statusNCT00019474Phase 2
15Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid TumorsUnknown statusNCT01177007Phase 2
16The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid CancerUnknown statusNCT01739634Phase 1, Phase 2
17IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and MelanomaUnknown statusNCT00294476Phase 2
18Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver CancerUnknown statusNCT00553683Phase 1, Phase 2
19Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel ObstructionCompletedNCT00004911Phase 1, Phase 2
20The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine TumorsCompletedNCT00627198Phase 2
21Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal ObstructionCompletedNCT00004910Phase 1, Phase 2
2268Ga-OPS202 Study for Diagnostic Imaging of GEP NETCompletedNCT02162446Phase 1, Phase 2
23Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal CancerCompletedNCT00005049Phase 2
24Study of LX1606 in Subjects With Symptomatic Carcinoid SyndromeCompletedNCT01104415Phase 2
25Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal CancerCompletedNCT00903396Phase 2
26Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide TherapyCompletedNCT00853047Phase 2
27Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerCompletedNCT00096083Phase 2
28Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver MetastasesCompletedNCT01290536Phase 2
29Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
30Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced CancerCompletedNCT00002475Phase 2
31Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1, Phase 2
32Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the LiverCompletedNCT00041808Phase 1, Phase 2
33TheraSphere for the Treatment of Liver MetastasesCompletedNCT00511862Phase 2
34Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver MetastasesCompletedNCT00019786Phase 2
35A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...CompletedNCT00923481Phase 2
36Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain MetastasesCompletedNCT00587964Phase 2
37Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours StudyRecruitingNCT02358356Phase 2
38Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mgRecruitingNCT02651987Phase 2
39A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorRecruitingNCT01994213Phase 2
40Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver MetastasesRecruitingNCT02185443Phase 2
41A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine CarcinomasRecruitingNCT02215447Phase 2
42Nivolumab and Ipilimumab in Treating Patients With Rare TumorsRecruitingNCT02834013Phase 2
43Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)RecruitingNCT02568267Phase 2
44Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic OriginRecruitingNCT02687958Phase 2
45Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerRecruitingNCT00445965Phase 2
46Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by SurgeryRecruitingNCT02595424Phase 2
47PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCERRecruitingNCT01037790Phase 2
48Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETActive, not recruitingNCT02231762Phase 2
49Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)Active, not recruitingNCT01253161Phase 2
50Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerActive, not recruitingNCT00514046Phase 1, Phase 2

Search NIH Clinical Center for Carcinoid Tumors, Intestinal


Cochrane evidence based reviews: carcinoid tumor

Genetic Tests for Carcinoid Tumors, Intestinal

About this section

Anatomical Context for Carcinoid Tumors, Intestinal

About this section

MalaCards organs/tissues related to Carcinoid Tumors, Intestinal:

35
Liver, Breast, Lung, Small intestine, Colon, Thyroid, Prostate

Animal Models for Carcinoid Tumors, Intestinal or affiliated genes

About this section

MGI Mouse Phenotypes related to Carcinoid Tumors, Intestinal:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.2MEN1, NKX2-1, NOTCH1, POMC, SDHD
2MP:00053818.9MEN1, NKX2-1, NOTCH1, SST, SSTR2
3MP:00053798.3CHGA, CHGB, MEN1, NKX2-1, NOTCH1, POMC
4MP:00053858.1CHGA, MEN1, NKX2-1, NOTCH1, POMC, SDHD
5MP:00053767.0CHGA, CHGB, MEN1, NKX2-1, NOTCH1, POMC
6MP:00036316.1CHGB, MEN1, NKX2-1, NOTCH1, POMC, SDHD

Publications for Carcinoid Tumors, Intestinal

About this section

Variations for Carcinoid Tumors, Intestinal

About this section

Expression for genes affiliated with Carcinoid Tumors, Intestinal

About this section
Search GEO for disease gene expression data for Carcinoid Tumors, Intestinal.

Pathways for genes affiliated with Carcinoid Tumors, Intestinal

About this section

GO Terms for genes affiliated with Carcinoid Tumors, Intestinal

About this section

Cellular components related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1secretory granuleGO:00301419.0CHGA, CHGB, POMC

Biological processes related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1neuron fate commitmentGO:004866310.4NKX2-1, NOTCH1
2oligodendrocyte differentiationGO:004870910.2NKX2-1, NOTCH1
3endoderm developmentGO:000749210.1NKX2-1, NOTCH1
4negative regulation of osteoblast differentiationGO:004566810.1MEN1, NOTCH1
5negative regulation of cell-substrate adhesionGO:00108129.8MEN1, NOTCH1
6brain developmentGO:00074209.2MEN1, NKX2-1, NOTCH1
7cell-cell signalingGO:00072679.0POMC, SST, SSTR2
8forebrain developmentGO:00309009.0NKX2-1, NOTCH1, SSTR2
9negative regulation of cell proliferationGO:00082858.0MEN1, NOTCH1, SST, SSTR2

Molecular functions related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1hormone activityGO:00051798.9CHGB, POMC, SST

Sources for Carcinoid Tumors, Intestinal

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet